Hongmo Biological HMO Helps Promote the High Quality Development of Chinese Infant Formula Milk Powder
Recently, Mengniu Ruibu En officially announced the launch of its first breast milk oligosaccharide (HMO) formula milk powder - Ruibu En En to Stage 4, injecting new vitality into the infant and toddler nutrition industry.
This innovative product specifically includes SynauraTMHMO, a breast milk oligosaccharide independently developed by Hongmu Biotechnology. This ingredient successfully passed the approval of the National Health Commission on October 7, 2023, and Hongmu Biotechnology became the only Chinese local enterprise among the first batch of approved enterprises. This milestone achievement not only highlights the leading position of Hongmo Biotechnology in the field of "local independent research and development", but also demonstrates its outstanding contribution in the innovation of infant and toddler nutrition technology.
Breast milk oligosaccharides (HMO) are the third largest solid component in breast milk, second only to lactose and fat, and play a crucial role in promoting immune regulation, cognitive enhancement, and intestinal health in infants and young children. The health benefits of HMO have been confirmed by multiple basic and clinical studies, and its importance for the growth and development of infants and young children has been widely recognized in the industry.
Having a deep understanding of the key role of HMO, global milk powder industry giants have already begun to conduct in-depth research. For a long time, the industrialization technology of HMO has been firmly held in the hands of European and American giants, which has become a bottleneck problem in the research and development and production of HMO raw materials in China, and also a constraint on the high-quality development of China's dairy industry. In this context, the breakthrough innovation of Hongmo Biotechnology is particularly important and exciting. The six words "local independent research and development" play a significant role in the case of Hongmo Biotechnology, and the industrial application of HMO has also helped China's dairy industry make great strides towards high-quality development.
The advantages of Hongmo Biotechnology in developing HMO are not only reflected in its local research and development capabilities, but also in its industry-leading product performance. Laboratory data shows that HMO independently developed by Hongmo Biotechnology achieves high purity, low impurities, and no odor. This series of data not only proves the high standards and excellent performance of HMO independently developed by Hongmo Biotechnology, but also provides strong quality assurance for domestic dairy products, leading the industry towards higher quality development.
From the development trajectory of the industry, Chinese infant formula milk powder has gone through the initial stage of balanced addition of basic nutrients (such as protein, fat, carbohydrates, vitamins and minerals), the strengthening stage of adding representative nutrients such as DHA, lactoferrin, OPO, and now fully entering the era of HMO application.
With the continuous progress and joint efforts of Chinese biotechnology companies such as Hongmo Biotechnology, more innovation and scientific research achievements will be transformed into practical applications, promoting the high-quality development of China's infant formula milk powder industry. Although this journey is far away, it is approaching.
Copyright © By 沪ICP备2024048832号 All Rights Reserved.